ALK-Abelló A/S
AKABY
Other OTC90.00
USD
- -
- -
ALK-Abelló A/S
AKABY
(Other OTC)
Recent
price
90.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ALK-Abelló A/S stands as a prominent global pharmaceutical entity, dedicated to pioneering comprehensive allergy solutions across Europe, North America, and other international markets. The company specializes in disease-modifying allergy immunotherapy (AIT) products, which address the underlying causes of various allergic conditions rather than just managing symptoms. These advanced treatments are available in diverse forms, including sublingual tablets, drops, and subcutaneous injections, targeting prevalent allergies such as house dust mite, grass pollen, tree pollen, ragweed, and Japanese cedar. Key therapeutic offerings include ACARIZAX/ODACTRA for house dust mite allergy, GRAZAX/GRASTEK for grass pollen, RAGWITEK/RAGWIZAX for ragweed, ITULAZAX/ITULATEK, and CEDARCURE. Beyond immunotherapy, ALK-Abelló supplies emergency adrenaline auto-injectors, such as Jext, for severe allergic reactions, and recently enhanced its anaphylaxis portfolio by licensing the adrenaline nasal spray neffy. The company also provides essential diagnostic tools and allergen extracts for allergy testing. Founded in 1923, ALK-Abelló A/S maintains its headquarters in Hørsholm, Denmark, and continues its mission to improve the lives of millions worldwide through its commitment to allergy research and treatment.